Literature DB >> 33322398

Effect of α-Hemolysin Producing E. coli in Two Different Mouse Strains in a DSS Model of Inflammatory Bowel Disease.

Hengameh Chloé Mirsepasi-Lauridsen1,2,3,4, Carsten Struve1, Andreas Munk Petersen5,6, Karen Angeliki Krogfelt4,7.   

Abstract

BACKGROUND: Phylogroup B2 Escherichia coli have been associated with ulcerative colitis (UC). In this study, we aimed to compare colonization with the UC-associated E. coli p19A in different mice strains, to investigate the role of alpha hemolysin in a UC mouse model.
METHODS: In this study, Sigirr -/- and C57BL/6 mice were chosen, and UC was induced by adding dextran sulfate sodium (DSS) to the drinking water. The mice were pre-treated with ciprofloxacin. p19A expressing luminescence and GFP, alpha-hemolysin knock out p19A-ΔhlyI II, and non-pathogenic lab E. coli DH10B were cultured in LB broth, and orally gavaged into the mice. Colonization with p19A WT was visualized using an in vivo imaging system.
RESULTS: p19A WT colonized the colon, ileum, Peyer's patches, liver, and spleen of infected C57BL/6 and Sigirr -/- mice. A total of 99% of the p19A WT infected C57BL/6 mice and 29% of the p19A WT infected Sigirr -/- mice survived to the 4th post infection day.
CONCLUSION: UC-associated E. coli p19A WT colonized the intestines of DSS-treated mice and caused extra-intestinal infection. Hemolysin is an important factor in this pathogenesis, since isogenic hemolysin mutants did not cause the same inflammation.

Entities:  

Keywords:  C57BL/6-mice; Escherichia coli; Sigirr −/− mice; alpha hemolysin; inflammatory-bowel-disease

Year:  2020        PMID: 33322398      PMCID: PMC7764192          DOI: 10.3390/microorganisms8121971

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  42 in total

Review 1.  Innate immune signaling in defense against intestinal microbes.

Authors:  Melissa A Kinnebrew; Eric G Pamer
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria.

Authors:  Chin Wen Png; Sara K Lindén; Kristen S Gilshenan; Erwin G Zoetendal; Chris S McSweeney; Lindsay I Sly; Michael A McGuckin; Timothy H J Florin
Journal:  Am J Gastroenterol       Date:  2010-07-20       Impact factor: 10.864

3.  Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease.

Authors:  M H Giaffer; C D Holdsworth; B I Duerden
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 4.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

5.  Comparative genomics of Escherichia coli strains causing urinary tract infections.

Authors:  Rebecca Munk Vejborg; Viktoria Hancock; Mark A Schembri; Per Klemm
Journal:  Appl Environ Microbiol       Date:  2011-03-18       Impact factor: 4.792

6.  Reduced mucosal antimicrobial activity in Crohn's disease of the colon.

Authors:  Sabine Nuding; Klaus Fellermann; Jan Wehkamp; Eduard F Stange
Journal:  Gut       Date:  2007-04-24       Impact factor: 23.059

7.  Dynamics of Escherichia coli infection and meningitis in infant rats.

Authors:  R Bortolussi; P Ferrieri; L W Wannamaker
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

8.  The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.

Authors:  Hui Xiao; Muhammet Fatih Gulen; Jinzhong Qin; Jianhong Yao; Katarzyna Bulek; Danielle Kish; Cengiz Zubeyir Altuntas; David Wald; Caixia Ma; Hang Zhou; Vincent K Tuohy; Robert L Fairchild; Carol de la Motte; Daniel Cua; Bruce A Vallance; Xiaoxia Li
Journal:  Immunity       Date:  2007-03-29       Impact factor: 31.745

Review 9.  Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials.

Authors:  Martin Feller; Karin Huwiler; Alain Schoepfer; Aijing Shang; Hansjakob Furrer; Matthias Egger
Journal:  Clin Infect Dis       Date:  2010-02-15       Impact factor: 9.079

10.  α-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon.

Authors:  Roland Bücker; Emanuel Schulz; Dorothee Günzel; Christian Bojarski; In-Fah M Lee; Lena J John; Stephanie Wiegand; Traute Janßen; Lothar H Wieler; Ulrich Dobrindt; Lothar Beutin; Christa Ewers; Michael Fromm; Britta Siegmund; Hanno Troeger; Jörg-Dieter Schulzke
Journal:  Gut       Date:  2014-02-17       Impact factor: 23.059

View more
  1 in total

1.  Substantial Intestinal Microbiota Differences Between Patients With Ulcerative Colitis From Ghana and Denmark.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Katleen Vranckx; Henrik Vedel Nielsen; Lee O'Brien Andersen; Timothy Archampong; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Front Cell Infect Microbiol       Date:  2022-03-03       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.